7d
MedPage Today on MSNYoung Patient Dies After Receiving New Gene Therapy for Duchenne Muscular DystrophyA young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
3don MSN
An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.
A patient has died following treatment with Elevidys, the Sarepta Therapeutics product that is the only FDA-approved gene therapy for Duchenne muscular dystrophy, the company disclosed Tuesday.
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...
5d
Clinical Trials Arena on MSNRegenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-oldThe interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...
A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the ...
It’s the first known patient death with the therapy, which has been ... about its effectiveness in treating Duchenne muscular dystrophy. It’s the first gene therapy approved in the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results